BYSI News and Press, BeyondSpring Inc. From 04/05/21

BeyondSpring (BYSI) is likely to receive regulatory approval for plinabulin/granulocyte colony-stimulating factor combination for the prevention of chemotherapy-induced neutropenia (“CIN”) argues H.C. Wainright analyst Joseph Pantginis.Expecting the product revenue to start from...

Citi expects makers of healthcare equipment to recover as vaccinations drive down COVID-19 infections and procedures return. Surging Invitae after Softbank-backed investment gets another boost as Oppenheimer upgrades the stock. Equipment makers to benefit from recovery trade Citi analysts are...

BeyondSpring (BYSI) has submitted a New Drug Application ((NDA)) to the FDA and the China National Medical Products Administration for use of plinabulin in combination with granulocyte colony-stimulating factor (G-CSF) for the prevention of chemotherapy-induced neutropenia ((CIN)). The NDA is...

– Applications are supported by positive PROTECTIVE-2 Phase 3 data demonstrating that plinabulin in combination with G-CSF offers greater protection against CIN than the standard of care, G-CSF alone – Plinabulin’s MoA is distinct from, yet complementary to th...

Today, we take an in-depth look at BeyondSpring, a small cap concern focused on the development of immuno-oncology cancer therapies. In recent months, the company has addressed its current funding needs and continues to advance its pipeline. A couple of NDA submissions loom on the...

Webinar on Thursday, March 18 th @ 10:00 a.m. ET NEW YORK, March 11, 2021 (GLOBE NEWSWIRE) -- BeyondSpring (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer t...

NEW YORK, Dec. 29, 2020 (GLOBE NEWSWIRE) -- BeyondSpring (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that CEO Dr. Lan Huang is scheduled to present...

NEW YORK, Dec. 29, 2020 (GLOBE NEWSWIRE) -- BeyondSpring (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that CEO Dr. Lan Huang is scheduled to present...

NEW YORK, Dec. 17, 2020 (GLOBE NEWSWIRE) -- BeyondSpring (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced the appointment of Dr. Jeffrey Vacirca to its ...

BYSI's lead candidate plinabulin in combo with Neulasta reduces grade 4 neutropenia in chemo patients better than Neulasta alone. However, the company is in perpetual cash-hungry mode, and every time it raises cash, the stock suffers. Catalysts are about a year ahead, but dilution...